Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 3
2005 2
2006 4
2007 1
2008 1
2009 4
2010 1
2011 4
2014 8
2015 7
2016 7
2017 4
2018 4
2019 7
2020 5
2021 5
2022 15
2023 14
2024 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma.
Matsuo Y, Ashida K, Nagayama A, Moritaka K, Gobaru M, Yasuda J, Ogasawara N, Kurose H, Chikui K, Iwata S, Inoguchi Y, Hasuzawa N, Motomura S, Igawa T, Nomura M. Matsuo Y, et al. Among authors: igawa t. Endocr Oncol. 2023 Aug 29;3(1):e230006. doi: 10.1530/EO-23-0006. eCollection 2023 Jan 1. Endocr Oncol. 2023. PMID: 37822367 Free PMC article.
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study.
Shiota M, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Sekine Y, Kimura H, Narita S, Terada N, Momozawa Y, Akamatsu S, Habuchi T, Yokomizo A, Naito S, Eto M. Shiota M, et al. Among authors: igawa t. Endocr Relat Cancer. 2023 Jun 1;30(7):e230044. doi: 10.1530/ERC-23-0044. Print 2023 Jul 1. Endocr Relat Cancer. 2023. PMID: 37079309
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, Kamoto T, Terada N, Kawahara K, Enokida H, Tatarano S, Fujimoto N, Higasijima K, Sakai H, Hakariya T, Igawa T, Suekane S, Kamba T, Sugiyama Y, Kishimoto J, Naito S. Yokomizo A, et al. Among authors: igawa t. Int J Urol. 2024 Apr;31(4):362-369. doi: 10.1111/iju.15371. Epub 2023 Dec 26. Int J Urol. 2024. PMID: 38148124 Clinical Trial.
Incidence and molecular characteristics of deficient mismatch repair conditions across nine different tumors and identification of germline variants involved in Lynch-like syndrome.
Ito T, Yamaguchi T, Kumamoto K, Suzuki O, Chika N, Kawakami S, Nagai T, Igawa T, Fujiyoshi K, Akagi Y, Arai T, Akagi K, Eguchi H, Okazaki Y, Ishida H. Ito T, et al. Among authors: igawa t. Int J Clin Oncol. 2024 Jul;29(7):953-963. doi: 10.1007/s10147-024-02518-y. Epub 2024 Apr 14. Int J Clin Oncol. 2024. PMID: 38615286 Free PMC article.
[Lymphnode metastasis].
Suekane S, Ueda K, Igawa T. Suekane S, et al. Among authors: igawa t. Nihon Rinsho. 2016 May 20;74 Suppl 3:149-53. Nihon Rinsho. 2016. PMID: 27344720 Japanese. No abstract available.
Survival outcomes of non-definitive therapy for muscle-invasive bladder cancer.
Nishihara K, Ueda K, Kurose H, Ogasawara N, Hiroshige T, Chikui K, Ejima K, Uemura K, Nakiri M, Suekane S, Igawa T. Nishihara K, et al. Among authors: igawa t. Oncol Lett. 2022 Apr;23(4):126. doi: 10.3892/ol.2022.13246. Epub 2022 Feb 17. Oncol Lett. 2022. PMID: 35261639 Free PMC article.
109 results